Virtual Library

Start Your Search

N. Gheroufella



Author of

  • +

    P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P1.01-066 - Maintenance Bevacizumab after Chemotherapy with Bevacizumab in First Line Treatment of Lung Cancer. A Single Institution Experience (ID 900)

      09:30 - 17:00  |  Author(s): N. Gheroufella

      • Abstract
      • Slides

      Background:
      Lung cancer is the first cancer in term of incidence and mortality for men in Algeria and a majority of the patients are stage IIIB or IV at the diagnostic. Bevacizumab + chemotherapy as first line followed by continuation maintenance with bevacizumab showed in many phase III randomized trial, an increase of PFS and overall survival. The purpose of this study is the evaluation of efficacy and toxicity of patient after continuation maintenance with bevacizumab in stage IIIB and IV for no squamous lung cancer in single institution.

      Methods:
      A retrospective study including all patients seen between September 2013 and April 2015, at department of medical oncology in Algiers. • Patients should have advanced or metastatic non squamous (adenocarcinoma and carcinoma with large cell) lung cancer, and received 4 cycles of induction chemotherapy with platine + pemetrexed + bevacizumab. • All patients with response or stable disease received bevacizumab as maintenance therapy, evaluation by CT scan was done every three cycles.

      Results:
      Twenty (3 F and 17 M) patients were enrolled, and all are evaluable for response and toxicity. Median age was 61.5 years (range m 31 years – M 74 years). Histology was adenocarcinoma in 19 patients and carcinoma with large cell in 1 patient. Sixteen (16) patients had IV stage and four (4) patients had IIIB stage disease. Response rate (1 CR, 4 PR) was seen in 5 patients (25 %), Stable Disease (SD) was achieved in 5 patients (25 %) and Progressive Disease (PD) in 10 patients (50 %). Among the 20 patients who achieved 4 cycles of induction bitherapy + bevacizumab, 10 patients (50 %) underwent for maintenance therapy. All the ten patients received the first three cycle of maintenance with bevacizumab and well tolerated without toxicity. At this time, two patients achieved one year maintenance with stabilization of disease. One of them developed hypertension and is under treatment.

      Conclusion:
      Bevacizumab was well tolerated in first line treatment and as maintenance, for patients with advanced or metastatic non-squamous lung cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.